Business
Website update
Website update.
About this update from Valirx Plc
[{"type":"text","content":"\n \nRNS Number : 9664G ValiRx PLC 20 May 2011 \n \n\n\n\n\n\n20 May 2011\n\n\n\n\n\n\n\n\n\n\n \nValiRx Plc\n(\"ValiRx\" or the \"Company\")\n \nWebsite update\n \nValiRx (AIM: VAL), a life science company with a focus on cancer diagnostics and therapeutics for personalised medicine, announces the following documents are now available to be downloaded from its website at www.valirx.com:-\n· ValiRx Research note dated 17 May 2011, prepared by the Company's broker Hybridan LLP\n· Investor presentation dated May 2011\n· Video presentation\n \nFor more information, please contact:\n \n\n\n\n\nValiRx plc\n\n\nTel: +44 (0) 20 3008 4416\n\n\n\n\nDr. Satu Vainikka\n\n\n\n\n\n\n\nwww.valirx.com\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCairn Financial Advisers LLP \n\n\n Tel: +44 (0) 20 7148 7900\n\n\n\n\nNominated Adviser\n\n\n\n\n\n\n\nLiam Murray / Avi Robinson\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nHybridan LLP \n\n\n Tel: +44 (0) 207 947 4350\n\n\n\n\nBroker \n\n\n\n\n\n\n\nClaire Noyce\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nPeckwater PR\n\n\n\n\n\n\n\nTarquin Edwards\n\n\nTel: +44 (0)7879 458 364\n\n\n\n\n\n\n\[email protected]\n\n\n\n\n \n \nNotes for Editors\n \nValiRx Plc\nValiRx Plc is a biopharmaceutical company developing novel technologies and products in oncology therapeutics and diagnostics. The product focus is in the epigenomic analysis and treatment of cancer, but the technologies can be applied to other fields as well, such as neurology and inflammatory diseases.\n \nThe Company listed on AIM in October 2006 and is creating a portfolio of innovative products through investment in specific development projects. It actively manages projects within this portfolio as a trading company and is not an investment vehicle. The ValiRx business model spreads the risks of life science technology developments by minimising financial exposure and running a set of projects to defined commercial endpoints. This maximises returns to shareholders by adding value at the earlier stages where value increases per investment unit are the greatest. \n \nThe Company operates through the following divisional companies:\n· ValiMedix is the sales and distribution...